Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor

Richard M. Goldberg, Joel M Reid, Matthew M. Ames, Jeff A Sloan, Joseph Rubin, Charles Erlichman, Mary J. Kuffel, Thomas R. Fitch

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Fazarabine (1-β-D-arabinofuranosyl-5-aza-cytosine, or Ara-AC) is a nucleoside analogue that consists of the arabinoside ring of 1-β-D- arabinofuranosylcytosine and the pyrimidine base of 5-azacytidine. In Phase I and Phase II trials, neutropenia was dose limiting, with minimal nonhematological toxicity. The in vitro cytotoxic concentrations of Ara-AC could not be achieved in these studies; neutropenia precluded dose escalation. The objectives of this study were: to determine either the maximum tolerated dose of Ara-AC or to safely achieve target plasma levels of 2-5 μg/ml when Ara-AC was administered as a 24-h infusion with granulocyte colony-stimulating factor (G-CSF) to patients with advanced refractory malignancies; to characterize the pharmacokinetic behavior of Ara-AC with G- CSF; and to define the relationship of Ara-AC pharmacokinetics to toxicity. Twenty-four patients received 67 courses of Ara-AC at doses of 54-112 mg/m2/h. Dose-limiting toxicity was approached but not reached. Grade 3 or 4 neutropenia and nausea were the principle side effects. Steady-state plasma concentrations exceeded the minimum target concentration of 2 μg/ml in all patients who received ≤78 mg/m2/h for 24 h. The maximum target concentration was approached during administration of 112 mg/m2/h for 24 h. The mean steady-state clearance was 475 ± 103 ml/min/m2 and did not change with dose. One partial response was seen. One patient received 16 courses and another received 7 courses of therapy before progression. Ara-AC can be safely administered in doses that result in plasma concentrations of 2-5 μg/ml, if it is given with G-CSF. Phase II trials of Ara-AC in selected malignancies are planned.

Original languageEnglish (US)
Pages (from-to)2363-2370
Number of pages8
JournalClinical Cancer Research
Volume3
Issue number12 I
StatePublished - Dec 1997

Fingerprint

fazarabine
Granulocyte Colony-Stimulating Factor
Pharmacology
Neutropenia
Pharmacokinetics
Azacitidine
Maximum Tolerated Dose
Cytosine
Cytarabine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Goldberg, R. M., Reid, J. M., Ames, M. M., Sloan, J. A., Rubin, J., Erlichman, C., ... Fitch, T. R. (1997). Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. Clinical Cancer Research, 3(12 I), 2363-2370.

Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. / Goldberg, Richard M.; Reid, Joel M; Ames, Matthew M.; Sloan, Jeff A; Rubin, Joseph; Erlichman, Charles; Kuffel, Mary J.; Fitch, Thomas R.

In: Clinical Cancer Research, Vol. 3, No. 12 I, 12.1997, p. 2363-2370.

Research output: Contribution to journalArticle

Goldberg, RM, Reid, JM, Ames, MM, Sloan, JA, Rubin, J, Erlichman, C, Kuffel, MJ & Fitch, TR 1997, 'Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor', Clinical Cancer Research, vol. 3, no. 12 I, pp. 2363-2370.
Goldberg, Richard M. ; Reid, Joel M ; Ames, Matthew M. ; Sloan, Jeff A ; Rubin, Joseph ; Erlichman, Charles ; Kuffel, Mary J. ; Fitch, Thomas R. / Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 12 I. pp. 2363-2370.
@article{a88d4af476ba49198620919ea6afba62,
title = "Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor",
abstract = "Fazarabine (1-β-D-arabinofuranosyl-5-aza-cytosine, or Ara-AC) is a nucleoside analogue that consists of the arabinoside ring of 1-β-D- arabinofuranosylcytosine and the pyrimidine base of 5-azacytidine. In Phase I and Phase II trials, neutropenia was dose limiting, with minimal nonhematological toxicity. The in vitro cytotoxic concentrations of Ara-AC could not be achieved in these studies; neutropenia precluded dose escalation. The objectives of this study were: to determine either the maximum tolerated dose of Ara-AC or to safely achieve target plasma levels of 2-5 μg/ml when Ara-AC was administered as a 24-h infusion with granulocyte colony-stimulating factor (G-CSF) to patients with advanced refractory malignancies; to characterize the pharmacokinetic behavior of Ara-AC with G- CSF; and to define the relationship of Ara-AC pharmacokinetics to toxicity. Twenty-four patients received 67 courses of Ara-AC at doses of 54-112 mg/m2/h. Dose-limiting toxicity was approached but not reached. Grade 3 or 4 neutropenia and nausea were the principle side effects. Steady-state plasma concentrations exceeded the minimum target concentration of 2 μg/ml in all patients who received ≤78 mg/m2/h for 24 h. The maximum target concentration was approached during administration of 112 mg/m2/h for 24 h. The mean steady-state clearance was 475 ± 103 ml/min/m2 and did not change with dose. One partial response was seen. One patient received 16 courses and another received 7 courses of therapy before progression. Ara-AC can be safely administered in doses that result in plasma concentrations of 2-5 μg/ml, if it is given with G-CSF. Phase II trials of Ara-AC in selected malignancies are planned.",
author = "Goldberg, {Richard M.} and Reid, {Joel M} and Ames, {Matthew M.} and Sloan, {Jeff A} and Joseph Rubin and Charles Erlichman and Kuffel, {Mary J.} and Fitch, {Thomas R.}",
year = "1997",
month = "12",
language = "English (US)",
volume = "3",
pages = "2363--2370",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12 I",

}

TY - JOUR

T1 - Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor

AU - Goldberg, Richard M.

AU - Reid, Joel M

AU - Ames, Matthew M.

AU - Sloan, Jeff A

AU - Rubin, Joseph

AU - Erlichman, Charles

AU - Kuffel, Mary J.

AU - Fitch, Thomas R.

PY - 1997/12

Y1 - 1997/12

N2 - Fazarabine (1-β-D-arabinofuranosyl-5-aza-cytosine, or Ara-AC) is a nucleoside analogue that consists of the arabinoside ring of 1-β-D- arabinofuranosylcytosine and the pyrimidine base of 5-azacytidine. In Phase I and Phase II trials, neutropenia was dose limiting, with minimal nonhematological toxicity. The in vitro cytotoxic concentrations of Ara-AC could not be achieved in these studies; neutropenia precluded dose escalation. The objectives of this study were: to determine either the maximum tolerated dose of Ara-AC or to safely achieve target plasma levels of 2-5 μg/ml when Ara-AC was administered as a 24-h infusion with granulocyte colony-stimulating factor (G-CSF) to patients with advanced refractory malignancies; to characterize the pharmacokinetic behavior of Ara-AC with G- CSF; and to define the relationship of Ara-AC pharmacokinetics to toxicity. Twenty-four patients received 67 courses of Ara-AC at doses of 54-112 mg/m2/h. Dose-limiting toxicity was approached but not reached. Grade 3 or 4 neutropenia and nausea were the principle side effects. Steady-state plasma concentrations exceeded the minimum target concentration of 2 μg/ml in all patients who received ≤78 mg/m2/h for 24 h. The maximum target concentration was approached during administration of 112 mg/m2/h for 24 h. The mean steady-state clearance was 475 ± 103 ml/min/m2 and did not change with dose. One partial response was seen. One patient received 16 courses and another received 7 courses of therapy before progression. Ara-AC can be safely administered in doses that result in plasma concentrations of 2-5 μg/ml, if it is given with G-CSF. Phase II trials of Ara-AC in selected malignancies are planned.

AB - Fazarabine (1-β-D-arabinofuranosyl-5-aza-cytosine, or Ara-AC) is a nucleoside analogue that consists of the arabinoside ring of 1-β-D- arabinofuranosylcytosine and the pyrimidine base of 5-azacytidine. In Phase I and Phase II trials, neutropenia was dose limiting, with minimal nonhematological toxicity. The in vitro cytotoxic concentrations of Ara-AC could not be achieved in these studies; neutropenia precluded dose escalation. The objectives of this study were: to determine either the maximum tolerated dose of Ara-AC or to safely achieve target plasma levels of 2-5 μg/ml when Ara-AC was administered as a 24-h infusion with granulocyte colony-stimulating factor (G-CSF) to patients with advanced refractory malignancies; to characterize the pharmacokinetic behavior of Ara-AC with G- CSF; and to define the relationship of Ara-AC pharmacokinetics to toxicity. Twenty-four patients received 67 courses of Ara-AC at doses of 54-112 mg/m2/h. Dose-limiting toxicity was approached but not reached. Grade 3 or 4 neutropenia and nausea were the principle side effects. Steady-state plasma concentrations exceeded the minimum target concentration of 2 μg/ml in all patients who received ≤78 mg/m2/h for 24 h. The maximum target concentration was approached during administration of 112 mg/m2/h for 24 h. The mean steady-state clearance was 475 ± 103 ml/min/m2 and did not change with dose. One partial response was seen. One patient received 16 courses and another received 7 courses of therapy before progression. Ara-AC can be safely administered in doses that result in plasma concentrations of 2-5 μg/ml, if it is given with G-CSF. Phase II trials of Ara-AC in selected malignancies are planned.

UR - http://www.scopus.com/inward/record.url?scp=0031418053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031418053&partnerID=8YFLogxK

M3 - Article

C2 - 9815635

AN - SCOPUS:0031418053

VL - 3

SP - 2363

EP - 2370

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12 I

ER -